Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endocyte Inc (ECYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 59,186
  • Shares Outstanding, K 42,580
  • Annual Sales, $ 70 K
  • Annual Income, $ -43,890 K
  • 36-Month Beta 1.62
  • Price/Sales 839.34
  • Price/Cash Flow 0.00
  • Price/Book 0.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.24 +12.10%
on 08/23/17
1.48 -6.08%
on 09/14/17
+0.15 (+12.10%)
since 08/22/17
3-Month
1.17 +18.80%
on 08/21/17
1.71 -18.71%
on 06/23/17
-0.28 (-16.77%)
since 06/22/17
52-Week
1.17 +18.80%
on 08/21/17
3.49 -60.17%
on 10/05/16
-1.75 (-55.73%)
since 09/22/16

Most Recent Stories

More News
Endocyte to Present at the 2017 Cantor Global Healthcare Conference

Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management...

ECYT : 1.39 (+0.72%)
Biotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte

If you want a Stock Review on CLVS, DERM, EDIT, or ECYT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, September 14, 2017, US markets...

DERM : 26.24 (-1.20%)
CLVS : 78.56 (+2.09%)
ECYT : 1.39 (+0.72%)
EDIT : 22.85 (-1.34%)
Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy

- Poster further demonstrates the potential of Endocyte's SMDC CAR-T platform to more safely regulate CAR-T therapy for solid tumors -

ECYT : 1.39 (+0.72%)
Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO)

Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that a poster will be presented...

ECYT : 1.39 (+0.72%)
Biotech Stocks on Investors' Radar -- Dermira, Endocyte, FibroGen, and Global Blood Therapeutics

If you want a Stock Review on DERM, ECYT, FGEN, or GBT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, August 10, 2017, US markets...

DERM : 26.24 (-1.20%)
GBT : 28.50 (+4.97%)
ECYT : 1.39 (+0.72%)
FGEN : 51.35 (-2.93%)
Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss

Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.

ENZ : 10.45 (-0.10%)
SMMT : 12.68 (+0.36%)
ECYT : 1.39 (+0.72%)
ADRO : 10.80 (-1.82%)
Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update

- Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 -

ECYT : 1.39 (+0.72%)
Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat

Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.

SPPI : 9.45 (-3.67%)
SMMT : 12.68 (+0.36%)
IMDZ : 10.50 (+1.45%)
ECYT : 1.39 (+0.72%)
Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

SMMT : 12.68 (+0.36%)
IMDZ : 10.50 (+1.45%)
ECYT : 1.39 (+0.72%)
SHPG : 155.09 (-0.17%)
What's in Store for Endocyte (ECYT) this Earnings Season?

Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.

AGEN : 4.10 (unch)
CLVS : 78.56 (+2.09%)
ECYT : 1.39 (+0.72%)
ICPT : 61.59 (-16.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based...

See More

Support & Resistance

2nd Resistance Point 1.40
1st Resistance Point 1.40
Last Price 1.39
1st Support Level 1.38
2nd Support Level 1.37

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.